Jounce Therapeutics Statistics Share Statistics Jounce Therapeutics has 52.64M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 52.64M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 29.81M Failed to Deliver (FTD) Shares 29,933 FTD / Avg. Volume 0.86%
Short Selling Information The latest short interest is 1.86M, so 0% of the outstanding
shares have been sold short.
Short Interest 1.86M Short % of Shares Out n/a Short % of Float 4.23% Short Ratio (days to cover) 2.62
Valuation Ratios The PE ratio is -1.13 and the forward
PE ratio is null.
Jounce Therapeutics's PEG ratio is
0.02.
PE Ratio -1.13 Forward PE n/a PS Ratio 0.7 Forward PS n/a PB Ratio 0.31 P/FCF Ratio -1.93 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Jounce Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.37,
with a Debt / Equity ratio of 0.05.
Current Ratio 8.37 Quick Ratio 8.37 Debt / Equity 0.05 Debt / EBITDA -0.2 Debt / FCF -0.34 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $581.56K Profits Per Employee $-361.13K Employee Count 141 Asset Turnover 0.39 Inventory Turnover n/a
Taxes Income Tax 135K Effective Tax Rate -0.27%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.75, so Jounce Therapeutics's
price volatility has been higher than the market average.
Beta 0.75 52-Week Price Change n/a 50-Day Moving Average 1.62 200-Day Moving Average 1.97 Relative Strength Index (RSI) 59.52 Average Volume (20 Days) 3,466,835
Income Statement In the last 12 months, Jounce Therapeutics had revenue of 82M
and earned -50.92M
in profits. Earnings per share was -0.99.
Revenue 82M Gross Profit 82M Operating Income -52.24M Net Income -50.92M EBITDA -50.16M EBIT -52.24M Earnings Per Share (EPS) -0.99
Full Income Statement Balance Sheet The company has 150.57M in cash and 10.02M in
debt, giving a net cash position of 140.55M.
Cash & Cash Equivalents 150.57M Total Debt 10.02M Net Cash 140.55M Retained Earnings -292.79M Total Assets 212.55M Working Capital 173.66M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -28.88M
and capital expenditures -919K, giving a free cash flow of -29.8M.
Operating Cash Flow -28.88M Capital Expenditures -919K Free Cash Flow -29.8M FCF Per Share -0.58
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -63.71% and -62.1%.
Gross Margin 100% Operating Margin -63.71% Pretax Margin -61.93% Profit Margin -62.1% EBITDA Margin -61.16% EBIT Margin -63.71% FCF Margin -36.34%
